SYSDIAGNO key facts
- Manufacturer of in vitro diagnostic kits designed for early detection of liver cancer in patients with chronic hepatitis B and cirrhosis.
- It has raised $14.8M; the latest was Later Stage VC in Jan 2025.
- Notable investors include CICC Capital, Beijing Bohua Capital, Nanjing Industrial Development Fund, RayStone Capital, Fosun Pharma — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch SYSDIAGNO: the Monday email on marks, rounds and moves
SYSDIAGNO funding rounds
No funding rounds for SYSDIAGNO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
SYSDIAGNO investors
9 investors are on record for SYSDIAGNO, including CICC Capital, Beijing Bohua Capital, Nanjing Industrial Development Fund and RayStone Capital.
About SYSDIAGNO
Manufacturer of in vitro diagnostic kits designed for early detection of liver cancer in patients with chronic hepatitis B and cirrhosis. The company offers a platform utilizing glycomics-based detection technology, which analyzes serum glycan profiles through capillary electrophoresis and AI-driven data interpretation, enabling healthcare providers to achieve higher sensitivity and specificity in liver cancer diagnostics, particularly in cases where traditional markers are insufficient.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2012
- Employees
- 20
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
SYSDIAGNO doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.